Key result
Excessive SPRR2B expression drives pathological cardiac fibroblast accumulation in heart failure via stress-dependent p53 degradation.
Why the study?
Does SPRR2B drive stress-dependent p53 degradation and fibroblast proliferation in heart failure?
Population
Cardiac fibroblasts from human heart failure patients and a mouse model of heart disease
Design
Preclinical
Authors
Loading...
SPRR2B may represent a therapeutic target to limit fibrosis in heart failure; extends preclinical mechanisms but leaves clinical translation open.
Does SPRR2B drive stress-dependent p53 degradation and fibroblast proliferation in heart failure?
SPRR2B drives pathological cardiac fibrosis in heart failure by promoting p53 degradation and fibroblast proliferation, identifying a potential novel therapeutic target.
Burke et al. (2018) studied Heart failure. SPRR2B was evaluated on p53 degradation and fibroblast proliferation. Excessive SPRR2B expression in cardiac fibroblasts drives stress-dependent p53 degradation and pathological fibroblast accumulation in heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: